Creative Medical Technology Holdings Inc (CELZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Creative Medical Technology Holdings Inc (CELZ) has a cash flow conversion efficiency ratio of -0.170x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.47 Million) by net assets ($8.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Creative Medical Technology Holdings Inc worth for the company's overall valuation and market capitalisation.
Creative Medical Technology Holdings Inc - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Creative Medical Technology Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Creative Medical Technology Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Creative Medical Technology Holdings Inc ranked by their cash flow conversion efficiency. Explore CELZ operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tantech Holdings Ltd
NASDAQ:TANH
|
-0.022x |
|
Nextage Therapeutics Ltd
TA:NXTG
|
0.311x |
|
Qiiwi Games AB (publ)
ST:QIIWI
|
-0.027x |
|
Witbe Net SA
PA:ALWIT
|
0.366x |
|
Ocean Glass Public Company Limited
BK:OGC
|
0.013x |
|
Biofil Chemicals & Pharmaceuticals Limited
NSE:BIOFILCHEM
|
-0.167x |
|
BTU Metals Corp
V:BTU
|
-0.015x |
|
Till Capital Ltd
V:TIL
|
-0.014x |
Annual Cash Flow Conversion Efficiency for Creative Medical Technology Holdings Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of Creative Medical Technology Holdings Inc from 2006 to 2025. View CELZ stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.52 Million | $-5.86 Million | -0.778x | +6.90% |
| 2024-12-31 | $6.34 Million | $-5.30 Million | -0.836x | -7.71% |
| 2023-12-31 | $10.34 Million | $-8.03 Million | -0.776x | -57.92% |
| 2022-12-31 | $15.86 Million | $-7.80 Million | -0.491x | -126.63% |
| 2021-12-31 | $10.22 Million | $-2.22 Million | -0.217x | -2086.29% |
| 2020-12-31 | $-39.80 Million | $-434.56K | 0.011x | -92.74% |
| 2019-12-31 | $-8.07 Million | $-1.21 Million | 0.150x | -42.95% |
| 2018-12-31 | $-3.99 Million | $-1.05 Million | 0.263x | -33.79% |
| 2017-12-31 | $-2.24 Million | $-889.62K | 0.398x | -85.90% |
| 2016-12-31 | $-157.79K | $-445.23K | 2.822x | +3443.05% |
| 2015-12-31 | $-183.80K | $-14.64K | 0.080x | -29.63% |
| 2014-12-31 | $-153.04K | $-17.32K | 0.113x | -38.23% |
| 2013-12-31 | $-125.03K | $-22.91K | 0.183x | +6.76% |
| 2012-12-31 | $-97.75K | $-16.77K | 0.172x | -11.29% |
| 2011-12-31 | $-72.16K | $-13.96K | 0.193x | -31.88% |
| 2010-12-31 | $-48.11K | $-13.66K | 0.284x | -71.50% |
| 2009-12-31 | $-30.85K | $-30.74K | 0.996x | +101.32% |
| 2008-12-31 | $757.00 | $-57.16K | -75.514x | -15375.15% |
| 2007-12-31 | $26.35K | $-12.86K | -0.488x | -995.05% |
| 2006-12-31 | $20.89K | $1.14K | 0.055x | -- |
About Creative Medical Technology Holdings Inc
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DD… Read more